Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer.

ABSTRACT:

Background

Pancreatic cancer is one of the most lethal tumors. The aim of this study is to provide an effective therapeutic discovery platform for pancreatic cancer by establishing and characterizing patient-derived organoids (PDOs).

Methods

PDOs were established from pancreatic tumor surgical specimens, and the mutations were examined using a panel sequence. Expression of markers was assessed by PCR, immunoblotting, and immunohistochemistry; tumorigenicity was examined using immunodeficient mice, and drug responses were examined in vitro and in vivo.

Results

PDOs were established from eight primary and metastatic tumors, and the characteristic mutations and expression of cancer stem cell markers and CA19-9 were confirmed. Tumorigenicity of the PDOs was confirmed in s

SUBMITTER: Watanabe S 

PROVIDER: S-EPMC9063137 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature